Myriad Genetics

Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic tests. It operates through the Diagnostics and Other segments. The Diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual's risk of developing a disease later in life. The Other segment offers testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and also includes corporate services. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Myriad Genetics reports robust Q4 growth and eyes market expansion

Myriad Genetics showcased strong revenue growth and strategic initiatives to drive profitability in Q4 2022.
The company's focus on customer engagement, product volumes, and market positioning reflects a commitment to growth and operational excellence.
Challenges in managing competition and optimizing operational efficiency are balanced by opportunities for revenue growth and market expansion.

Myriad Genetics reports strong Q1 earnings, eyes profitability in Q4

Myriad Genetics demonstrated robust performance in Q1, leveraging strategic partnerships and operational improvements to drive revenue growth and enhance testing volumes.
While facing challenges like billing issues and seasonality-related declines, the company remains focused on core products, profitability, and growth opportunities.
With a strong financial outlook, emphasis on innovation, and commercial initiatives, Myriad Genetics is well-positioned to capitalize on market opportunities and drive sustainable growth.

Myriad Genetics reports solid Q2 growth and strategic focus

Myriad Genetics showcased strong financial performance, operational efficiencies, and strategic focus on growth and profitability.
While facing challenges like milestone payment concerns and industry competition, the company's strengths in key segments and operational capabilities position them well.
Opportunities in product enhancements, channel expansions, and investor engagement pave the way for continued success and market leadership.

Myriad Genetics reports strong Q3 earnings and raises 2024 guidance

Myriad Genetics reported strong revenue growth and operational improvements, with a focus on key product lines and enhancing customer experience.
The company raised financial guidance for 2023 and introduced revenue guidance for 2024, showcasing confidence in achieving long-term growth targets.
Challenges include regulatory changes, market penetration, and maintaining profitability amidst competitive dynamics, while opportunities lie in sustained growth and revenue optimization.
Overall, Myriad Genetics demonstrated resilience and strategic focus in driving growth, improving margins, and navigating market challenges effectively.

Myriad Genetics reports strong Q4 performance and eyes market expansion

Myriad Genetics delivered a strong Q4 performance with a focus on growth, strategic investments, and operational improvements. The company faces challenges in pricing and reimbursement but sees opportunities in market expansion and new product launches. Overall, Myriad Genetics is optimistic about its future prospects and market positioning.

Myriad Genetics reports robust Q1 performance and eyes growth opportunities

Myriad Genetics delivered a strong quarter with revenue growth and positive EBITDA, focusing on strategic areas like oncology and women's health. The company is optimistic about exceeding guidance but remains cautious. Analysts raised inquiries about various segments and operational decisions, with the company emphasizing profitable growth and maintaining margins.

Myriad Genetics reports strong Q2 performance and raises revenue targets

Myriad Genetics delivered a robust Q2 performance with revenue growth, positive earnings, and strategic wins in payer coverage, setting the stage for continued growth.
The company's focus on efficiency, customer satisfaction, and profitable growth positions it well for future success amidst market challenges and opportunities.
With raised revenue targets, expanded market acceptance, and operational excellence, Myriad Genetics demonstrates resilience and adaptability in a dynamic healthcare landscape.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GREENVILLE, S.C.--(BUSINESS WIRE)--Kiyatec, a leading functional precision oncology company specializing in 3D cell culture technology and delivering evidence of therapeutic response in the oncology space, is pleased to announce that Mark Capone, former CEO of Myriad Genetics, has joined its team as a strategic advisor. Mr. Capone is an accomplished life sciences CEO with almost 40 years of experience in molecular diagnostics, genetics, biotechnology, medical devices, and pharmaceuticals. He ha.

Kiyatec strengthens its leadership position with the addition of Mark Capone, former CEO of Myriad Genetics, as Strategic Advisor

SALT LAKE CITY, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has delivered results to one million consumers with its SneakPeek® Early Gender DNA Test. Since 2015, SneakPeek has been providing expectant families with an easy and convenient way to learn the sex of their baby as early as six weeks into pregnancy.

Myriad Genetics Celebrates One Million SneakPeek® Results Shared with Expectant Parents

Myriad Genetics (MYGN) will market the Personalis ImmunoID NeXT ultra-comprehensive biomarker discovery platform to its pharmaceutical partners with a new collaboration.

Myriad Genetics (MYGN) Expands Pharma Services With New Pact

Myriad expands pharma service offering by introducing Personalis' ImmunoID NeXT® platform to its pharmaceutical partners who use MyRisk® Hereditary Cancer Test, BRACAnalysis CDx® and/or MyChoice® CDx cancer tests Myriad expands pharma service offering by introducing Personalis' ImmunoID NeXT® platform to its pharmaceutical partners who use MyRisk® Hereditary Cancer Test, BRACAnalysis CDx® and/or MyChoice® CDx cancer tests

Myriad Genetics and Personalis Partner to Market Solutions to Pharma Customers

SALT LAKE CITY, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Myriad management will participate in the Stephens Annual Investment Conference in Nashville, TN with a fireside chat on Wednesday, November 15 at 2:00 p.m. ET.

Myriad Genetics to Participate in Stephens Annual Investment Conference

SALT LAKE CITY, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN) (the “Company” or “Myriad Genetics”), a leader in genetic testing and precision medicine, today announced the pricing of an upsized underwritten public offering of 6,470,588 shares of its common stock, par value $0.01 per share (“common stock”), at a public offering price of $17.00 per share for expected gross proceeds of approximately $110 million, before deducting the underwriting discounts and commissions and estimated offering expenses payable by the Company. The Company has also granted the underwriters a 30-day option to purchase up to an additional 970,588 shares of its common stock at the public offering price, less underwriting discounts and commissions. All of the shares in the offering are to be sold by the Company. The offering is expected to close on November 13, 2023, subject to customary closing conditions.

Myriad Genetics Announces Pricing of Upsized Offering of Common Stock

SALT LAKE CITY, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN) (the “Company” or “Myriad Genetics”), a leader in genetic testing and precision medicine, today announced that it plans to make a public offering of $100.0 million of shares of its common stock, par value $0.01 per share (“common stock”), in an underwritten registered public offering. The Company also expects to grant the underwriters a 30-day option to purchase up to $15.0 million of additional shares of its common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the final size or terms of the offering. All of the shares in the proposed offering are to be sold by the Company.

Myriad Genetics Announces Proposed Offering of $100 Million of Shares of Common Stock

Myriad Genetics' (MYGN) third-quarter 2023 revenues increase year over year, driven by strong testing volume improvement across all its businesses.

Myriad Genetics (MYGN) Posts Narrower-Than-Estimate Loss in Q3

The headline numbers for Myriad (MYGN) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Myriad (MYGN) Reports Q3 Earnings: What Key Metrics Have to Say

Myriad Genetics, Inc. (NASDAQ:MYGN ) Q3 2023 Earnings Conference Call November 6, 2023 4:30 PM ET Company Participants Matt Scalo - Senior Vice President, Investor Relations Paul Diaz - President and Chief Executive Officer Mark Verratti - Chief Commercial Officer Bryan Riggsbee - Chief Financial Officer Conference Call Participants Elizabeth Koslosky - Goldman Sachs Andrew Cooper - Raymond James Daniel Sammarco - TD Cowen Jack Meehan - Nephron Research Wolf Chanoff - Bank of America Matt Scalo Good afternoon and welcome to Myriad Genetics Third Quarter 2023 Earnings Call. During the call, we will review the financial results we released today.

Myriad Genetics, Inc. (MYGN) Q3 2023 Earnings Call Transcript

Highlights: Third quarter testing volume grew 18% year-over-year, excluding contributions from the SneakPeek ® Early Gender DNA Test, the fifth consecutive quarter of double-digit year-over-year growth. In the third quarter and year-to-date: Hereditary cancer test volumes grew 18% and 20% year-over-year, respectively.

Myriad Genetics Reports Third Quarter 2023 Financial Results; Generates Double-Digit Revenue Growth; Raises 2023 Revenue Guidance and Introduces 2024 Revenue Guidance

SALT LAKE CITY, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the appointment of Sam Raha as Chief Operating Officer (COO), effective December 11, 2023.

Myriad Genetics Appoints Sam Raha as Chief Operating Officer

SALT LAKE CITY, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its third quarter earnings conference call on Monday, November 6, 2023 at 4:30 p.m. EDT. The company's quarterly earnings will be released the same day after the market closes.

Myriad Genetics to Release Third Quarter Financial Results on November 6, 2023

SALT LAKE CITY , Sept. 28, 2023 /PRNewswire/ -- A new national survey from Myriad Genetics Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, revealed that breast density and family health history are two misunderstood breast cancer risk factors.

BREAST CANCER AWARENESS MONTH: NEW CANCER RISK SURVEY REVEALS RISK FACTORS ARE WIDELY MISUNDERSTOOD

SALT LAKE CITY, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics , Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced results from a nationwide survey revealing breast density and family health history are two misunderstood breast cancer risk factors.

New Myriad Genetics Survey Shows Breast Cancer Risk Factors Are Misunderstood

Myriad Genetics (MYGN) achieves significant milestones in its partnership with Illumina.

Myriad Genetics (MYGN) Secures Key Milestones in Illumina Tie-Up

Myriad Genetics (MYGN) announces a collaboration with Memorial Sloan Kettering Cancer Center to study the use of MRD testing in breast cancer.

Myriad Genetics' (MYGN) New Deal to Use MRD Testing Platform

Myriad can conduct prospective clinical trials using Illumina's TruSight Oncology Comprehensive Investigational Use Only test Myriad can conduct prospective clinical trials using Illumina's TruSight Oncology Comprehensive Investigational Use Only test

Myriad Genetics and Illumina Achieve Milestones in Strategic Partnership to Support Biopharma Clinical Trials

SALT LAKE CITY, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today released its second annual Environmental, Social and Governance report, highlighting key efforts that reflect its commitment to conduct operations as a responsible, equitable and sustainable partner in the healthcare industry.

Myriad Genetics Issues 2022 Environmental, Social and Governance Report

Research will use Myriad's high-definition MRD testing platform based on whole-genome sequencing Research will use Myriad's high-definition MRD testing platform based on whole-genome sequencing

Myriad Genetics and Leading Cancer Center Collaborate to Study the Use of Minimal Residual Disease Testing in Breast Cancer

Myriad Genetics is a leading molecular diagnostic company that focuses on developing and marketing predictive, personalized, and prognostic medicine tests. The company's financial metrics show multi-faceted performance, with revenue growth, strong gross margins, and prudent cost management. MYGN offers a range of innovative products but faces challenges such as validation and acceptance, accessibility and affordability, and regulatory requirements.

Myriad Genetics: FRα Addition Further Diversifies Portfolio

SALT LAKE CITY, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Great Place To Work® and Fortune magazine have named Myriad Genetics to the 2023 Fortune Best Workplaces in Health Care™ List.

Myriad Genetics Named to 2023 Best Workplaces in Health Care List by Fortune and Great Place To Work

Nearly three out of four women falsely believe a pap smear will reveal ovarian cancer presence Nearly three out of four women falsely believe a pap smear will reveal ovarian cancer presence

New Myriad Genetics Survey Reveals Widespread Confusion and Misconceptions About Ovarian Cancer Screening Among a Majority of Women

SALT LAKE CITY, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced management will participate in the Morgan Stanley 21st Annual Global Healthcare Conference with a fireside chat on Wednesday, Sept.

Myriad Genetics to Participate in Morgan Stanley Global Healthcare Conference

Myriad Genetics (MYGN) announces collaboration with Onsite Women's Health to develop a breast cancer risk assessment program.

News for Myriad Genetics Stock (MYGN)